Alba Migliorato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alba Migliorato has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Vita
University of Messina
14 shared publications - Carmelo Rodolico
Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy
13 shared publications - Anna Mazzeo
Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
9 shared publications A. Toscano
Department of Clinical and Experimental Medicine, University of Messina, Italy
6 shared publications- Mohammed Aguennouz
Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy
6 shared publications Alessandra Bitto
5 shared publications
Latest Publications
- 1 December 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26 (12) , 890-894
Ischemic stroke due to hypoperfusion in a patient with a previously unrecognized Danon disease
- 1 December 2016
- Published by Elsevier in Neuromuscular Disorders
- Vol. 26 (12) , 890-894
Ischemic stroke due to hypoperfusion in a patient with a previously unrecognized Danon disease
- 25 August 2016
- Published by Wiley in Cell Biochemistry and Function
- Vol. 34 (6) , 414-422
MicroRNA signatures predict dysregulated vitamin D receptor and calcium pathways status in limb girdle muscle dystrophies (LGMD) 2A/2B
MiRNA expression profile and predicted pathways involved in selected limb‐girdle muscular dystrophy (LGMD)2A/2B patients were investigated. A total of 187 miRNAs were dysregulated in all patients, with six miRNAs showing opposite regulation in LGMD2A versus LGMD2B patients. Silico analysis evidence: (1) a cluster of the dysregulated miRNAs resulted primarily involved in inflammation and calcium metabolism, and (2) two genes predicted as controlled by calcium‐assigned miRNAs (Vitamin D Receptor gene and Guanine Nucleotide Binding protein beta polypeptide 1gene) showed an evident upregulation in LGMD2B patients, in accordance with miRNA levels. Our data support alterations in calcium pathway status in LGMD 2A/B, suggesting myofibre calcium imbalance as a potential therapeutic target. Copyright © 2016 John Wiley & Sons, Ltd.
- 25 August 2016
- Published by Wiley in Cell Biochemistry and Function
- Vol. 34 (6) , 414-422
MicroRNA signatures predict dysregulated vitamin D receptor and calcium pathways status in limb girdle muscle dystrophies (LGMD) 2A/2B
MiRNA expression profile and predicted pathways involved in selected limb‐girdle muscular dystrophy (LGMD)2A/2B patients were investigated. A total of 187 miRNAs were dysregulated in all patients, with six miRNAs showing opposite regulation in LGMD2A versus LGMD2B patients. Silico analysis evidence: (1) a cluster of the dysregulated miRNAs resulted primarily involved in inflammation and calcium metabolism, and (2) two genes predicted as controlled by calcium‐assigned miRNAs (Vitamin D Receptor gene and Guanine Nucleotide Binding protein beta polypeptide 1gene) showed an evident upregulation in LGMD2B patients, in accordance with miRNA levels. Our data support alterations in calcium pathway status in LGMD 2A/B, suggesting myofibre calcium imbalance as a potential therapeutic target. Copyright © 2016 John Wiley & Sons, Ltd.
- 12 February 2015
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (4) , 968-978
Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment
Pompe disease is a rare metabolic disorder, due to mutations in the gene encoding acid alpha-glucosidase (GAA), of which infantile and late-onset forms may occur. Aim of the work was to analyze clinical and laboratory data of a cohort of late-onset Pompe disease (LOPD) patients, collected during the last 15 years and to point out unusual phenotypic/genotypic features as well as enzyme replacement therapy (ERT) responses. We diagnosed 30 LOPD patients; at follow-up, they underwent motor, respiratory, cardiac and muscle MRI evaluations. Motor performances were tested by Walton Gardner-Medwin, GSGC and 6MWT tests. Respiratory function was assessed as FVC % in upright/supine position. LOPD presentations were represented by presymptomatic hyperCKemia (37 %), proximal/axial muscle weakness (53 %) and respiratory impairment (10 %). Median diagnostic delay was 8.6 years (±8.8). Atypical features were observed in 4 patients: marked distal muscle weakness and severe hearing loss at onset, as well as leukoencephalopathy and mesial temporal sclerosis during the disease course. By GAA sequence analysis, two causing mutations were detected in 22/30 patients, only one in the remaining 8 subjects. Overall, 29/30 patients harbored the common c.−32−13T>G mutation (2 were homozygous). Two new DNA variations were discovered (c.2395C>G, c.1771C>T). 14 patients received ERT for up to 60 months. Our study confirms LOPD clinical and genetic heterogeneity: atypical features may contribute to expand the clinical phenotype highlighting its multi-systemic nature. A timely diagnosis could allow early ERT start. An accurate follow-up is recommended to evaluate treatment responses.
- 12 February 2015
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (4) , 968-978
Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment
Pompe disease is a rare metabolic disorder, due to mutations in the gene encoding acid alpha-glucosidase (GAA), of which infantile and late-onset forms may occur. Aim of the work was to analyze clinical and laboratory data of a cohort of late-onset Pompe disease (LOPD) patients, collected during the last 15 years and to point out unusual phenotypic/genotypic features as well as enzyme replacement therapy (ERT) responses. We diagnosed 30 LOPD patients; at follow-up, they underwent motor, respiratory, cardiac and muscle MRI evaluations. Motor performances were tested by Walton Gardner-Medwin, GSGC and 6MWT tests. Respiratory function was assessed as FVC % in upright/supine position. LOPD presentations were represented by presymptomatic hyperCKemia (37 %), proximal/axial muscle weakness (53 %) and respiratory impairment (10 %). Median diagnostic delay was 8.6 years (±8.8). Atypical features were observed in 4 patients: marked distal muscle weakness and severe hearing loss at onset, as well as leukoencephalopathy and mesial temporal sclerosis during the disease course. By GAA sequence analysis, two causing mutations were detected in 22/30 patients, only one in the remaining 8 subjects. Overall, 29/30 patients harbored the common c.−32−13T>G mutation (2 were homozygous). Two new DNA variations were discovered (c.2395C>G, c.1771C>T). 14 patients received ERT for up to 60 months. Our study confirms LOPD clinical and genetic heterogeneity: atypical features may contribute to expand the clinical phenotype highlighting its multi-systemic nature. A timely diagnosis could allow early ERT start. An accurate follow-up is recommended to evaluate treatment responses.
- 19 December 2014
- Published by Wiley in Muscle & Nerve
- Vol. 51 (6) , 934-935
Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone
- 19 December 2014
- Published by Wiley in Muscle & Nerve
- Vol. 51 (6) , 934-935
Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone
- 1 August 2011
- Published by Elsevier in Neuromuscular Disorders
- Vol. 21 (8) , 579-589
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice
- 1 August 2011
- Published by Elsevier in Neuromuscular Disorders
- Vol. 21 (8) , 579-589
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice
- 1 December 2009
- Published by Elsevier in Experimental Neurology
- Vol. 220 (2) , 349-358
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone
- 1 December 2009
- Published by Elsevier in Experimental Neurology
- Vol. 220 (2) , 349-358
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone
- 1 November 2008
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 48 (5) , 1292-1300
Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease
- 1 November 2008
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 48 (5) , 1292-1300
Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease
- 1 February 2008
- Published by Elsevier in Pharmacological Research
- Vol. 57 (2) , 159-169
Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes
- 1 February 2008
- Published by Elsevier in Pharmacological Research
- Vol. 57 (2) , 159-169
Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes
- 15 June 2007
- Published by Wiley in The FASEB Journal
- Vol. 21 (13) , 3737-3746
VEGF overexpression via adeno‐associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice
Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Recently it was reported that the delivery of VEGF using recombinant adeno‐associated virus (rAAV) vectors reduces muscle damage and promotes muscle regeneration in different experimental models of muscle necrosis. We demonstrate that intramuscular administration of rAAV‐VEGF improved pathophysiology of the mdx mouse, a model of Duchenne muscular dystrophy (DMD). One month after injection, rAAV‐VEGF‐treated muscles showed augmented expression of VEGF and immu‐nolocalization of its receptor, VEGFR‐2. VEGF‐treated mdx mice showed increased forelimb strength and strength normalized to weight. Treatment reduced necrotic fibers area and increased regenerating fibers area with an augmented number of myoge‐nin‐positive satellite cells and myonuclei, and of developmental myosin heavy chain‐positive fibers. Only the regenerating area showed increased capillary density. This study provides novel evidence of a VEGF beneficial effect in mdx mice that is exerted mainly by a proregenerative and angiogenic effect. It opens new therapeutic prospectives in DMD and other types of muscular disorders.—Messina S., Mazzeo, A., Bitto, A., Aguennouz, M., Migliorato, A., De Pasquale M. G., Minutoli, L., Altavilla, D., Zentilin L., Giacca, M., Squadrito, F., Vita G. VEGF overexpression via adeno‐associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J. 21, 3737–3746 (2007)
- 15 June 2007
- Published by Wiley in The FASEB Journal
- Vol. 21 (13) , 3737-3746
VEGF overexpression via adeno‐associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice
Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Recently it was reported that the delivery of VEGF using recombinant adeno‐associated virus (rAAV) vectors reduces muscle damage and promotes muscle regeneration in different experimental models of muscle necrosis. We demonstrate that intramuscular administration of rAAV‐VEGF improved pathophysiology of the mdx mouse, a model of Duchenne muscular dystrophy (DMD). One month after injection, rAAV‐VEGF‐treated muscles showed augmented expression of VEGF and immu‐nolocalization of its receptor, VEGFR‐2. VEGF‐treated mdx mice showed increased forelimb strength and strength normalized to weight. Treatment reduced necrotic fibers area and increased regenerating fibers area with an augmented number of myoge‐nin‐positive satellite cells and myonuclei, and of developmental myosin heavy chain‐positive fibers. Only the regenerating area showed increased capillary density. This study provides novel evidence of a VEGF beneficial effect in mdx mice that is exerted mainly by a proregenerative and angiogenic effect. It opens new therapeutic prospectives in DMD and other types of muscular disorders.—Messina S., Mazzeo, A., Bitto, A., Aguennouz, M., Migliorato, A., De Pasquale M. G., Minutoli, L., Altavilla, D., Zentilin L., Giacca, M., Squadrito, F., Vita G. VEGF overexpression via adeno‐associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J. 21, 3737–3746 (2007)
- 1 May 2006
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 174 (1-2) , 32-38
Immunolocalization and activation of nuclear factor-κB in the sciatic nerves of rats with experimental autoimmune neuritis
- 1 May 2006
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 174 (1-2) , 32-38
Immunolocalization and activation of nuclear factor-κB in the sciatic nerves of rats with experimental autoimmune neuritis